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Abstract The prevalence of chronic heart failure is still
increasing making it a major health issue in the 21st century.
Tremendous evidence has emerged over the past decades that
heart failure is associated with a wide array of mechanisms
subsumed under the term ‘‘inflammation’’. Based on the great
success of immuno-suppressive treatments in auto-immunity
and transplantation, clinical trials were launched targeting
inflammatory mediators in patients with chronic heart failure.
However, they widely lacked positive outcomes. The failure
of the initial study program directed against tumor necrosis
factor-a led to the search for alternative therapeutic targets
involving a broader spectrum of mechanisms besides cyto-
kines. We here provide an overview of the current knowledge
on immune activation in chronic heart failure of different
etiologies, summarize clinical studies in the field, address
unresolved key questions, and highlight some promising
novel therapeutic targets for clinical trials from a translational
basic science and clinical perspective.
Keywords Cytokines  Heart failure 
Immuno-modulation
Introduction
Congestive heart failure (CHF) is a leading cause for both
hospitalization and death in the western world. Its preva-
lence is rather increasing with the broad implementation of
standardized evidence-based treatment algorithms for heart
failure. The heart failure syndrome is characterized by
impaired systolic and/or diastolic function and various
clinical signs such as fatigue, dyspnea, fluid retention, and
cachexia. Besides symptomatic treatment to relieve these
symptoms several classes of drugs improve the prognosis
of patients with chronic heart failure. These agents target
the so-called neurohumoral activation process that comes
along with the evolution of the heart failure syndrome
irrespective of the underlying pathophysiology. Inhibition
of the activity of the renin–angiotensin–aldosterone system
and b-adrenergic signaling are well-established treatment
principles which are incorporated in current guidelines
[100]. However, morbidity and mortality remain sub-
stantial in chronic heart failure patients despite optimal
medical and device therapy, the indication for which has
recently been broadened [100].
An inflammatory activation in CHF patients has long
been recognized. Indeed, immune mechanisms modulate
interstitial fibrosis, cardiomyocyte apoptosis, and hyper-
trophy, all of which are central processes leading to mal-
adaptive remodeling in response to a variety of stimuli
(Fig. 1). Especially for heart failure evolving from large
myocardial infarction there is substantial evidence for a
causal contribution of immunity early in the course of the
disease.
First, systemic cytokines came into focus, which have
been monitored in several clinical trials [33, 112]. The
broadest amount of data was gathered for tumor necrosis
factor-a (TNF-a) [78] which was demonstrated to correlate
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well with diverse clinical and laboratory parameters, such
as exercise capacity and neurohormonal activation in CHF
patients [26]. These observations lead to the conduction of
clinical trials testing anti-TNF-a drugs in chronic heart
failure patients [25, 96]. Their discouraging results have
raised important questions on the significance of the
inflammatory activation in chronic heart failure. It is still
unresolved whether these trials treated the right patients
with the right drugs [4] or whether the whole concept of
anti-cytokine therapy mainly based on small animal studies
does not work in a heterogeneous population of patients
with chronic heart failure of diverse etiology.
Meanwhile, basic science and translational clinical
research gathered a lot of mechanistic information on new
players in the field of inflammation which constitute very
promising future targets for therapy. Therefore, a recent
scientific statement from the European Society of Cardi-
ology defined key questions and requirements for future
studies in the enormously expanding field [61].
The current review will provide the reader with an
elected overview of experimental and clinical evidence for
immune activation in chronic heart failure, summarize key
clinical trials addressing the immune system, and provide
an outlook for several new promising clinical targets.
Evidence for immune activation in heart failure
of different etiology
Different etiologies like coronary artery disease, hyper-
tension, infection, etc., lead to heart failure. Therefore, one
of the key questions in the field is whether activation of
immunity in humans and animal models of heart failure is
independent of the etiology or if there are disease specific
mechanisms. As it turns out, both are the case.
Different heart failure models indicate a role of innate
immunity independent of heart failure etiology. Innate
immunity is activated in the myocardium early by recog-
nition of rather unspecific stimuli, summarized as danger-
associated molecular patterns [10]. This form of sterile
inflammation is prototypically initiated by engagement of
innate pattern recognition receptors, like toll-like receptors
[68].
It is likely that inflammation is also initiated in human
myocardium by innate recognition of pathogen-associated
molecular pattern even well before the heart failure
becomes symptomatic/diagnosed. However, clinical data to
corroborate findings made in animal studies are widely
limited to the demonstration of increased circulating levels
of soluble mediators, mainly cytokines [78], in a variety of
patient cohorts with heart failure.
For heart failure with reduced ejection fraction due to
different clinical etiologies there is good evidence from
both experimental and clinical studies that pro-inflam-
matory cytokines are locally expressed in myocardium.
For example, TNF-a has been mechanistically related to
more or less all etiologies of systolic heart failure.
Besides its direct effect on myocardial contractile func-
tion [35, 155], TNF-a contributes to progressive myo-
cardial remodeling. This is underscored by the
demonstration that chronic systemic administration of
TNF-a in concentrations found in CHF patients [14] or its
transgenic myocardial expression produces a DCM-like
phenotype [79].
Fig. 1 Schematic overview
depicting activation
mechanisms of both innate and
adaptive immunity and their
central effector mechanism
reviewed here
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Nevertheless, there are also distinct differences in the
activation of the immune system in different heart failure
etiologies:
Ischemic heart failure
Heart failure due to large myocardial infarction is the most
prevalent cause of systolic heart failure, so the majority of
small animal studies for heart failure were conducted in the
permanent myocardial infarction model. Besides early
infiltration of leukocytes and local expression of cytokines
and chemokines, there is ongoing inflammation that
extends to the remote myocardium and is a part of the
underlying pathophysiology of left ventricular remodeling.
A detailed review of all the processes involved in myo-
cardial remodeling is beyond the scope of the present
article and was summarized recently [42]. Inflammation
mainly involves innate immunity mechanisms including
toll-like receptor activation [44, 68] and NFjB intracellular
signaling both in local cells (cardiomyocytes, fibroblasts)
and in infiltrating leukocytes [45]. Clinical evidence for the
activation of adaptive immunity is comparatively sparse.
However, the increased prevalence of auto-antibodies
against structural components of [30] and cell surface
receptors on cardiomyocytes [129] indicates that ischemic
injury can induce an adaptive auto-immune response
against myocardial tissue.
Most animal studies are performed in relatively acute
settings with follow-up of no longer than 8 weeks. Espe-
cially experiments with genetically altered mice often do
not really allow distinguishing the effect on initial myo-
cardial injury and wound healing, when the most pro-
nounced inflammatory activation takes place, from chronic
remodeling of the myocardium. Therefore, therapeutic
approaches based on such animal experiments rather reflect
the clinical situation weeks to months after a myocardial
infarction when mechanisms, such as infarct expansion are
still operative and do not easily allow transfer of the
findings to the situation of chronic, non-ischemic, systolic
heart failure.
In contrast to the broad evidence from small animal
studies, due to the limited availability of myocardial
specimens clinical evidence for immune activation in
chronic ischemic heart failure mainly comes from analysis
of cytokines and cytokine receptors in peripheral blood [8]
which first led to the design of anti-cytokine trials, as
summarized below.
Inflammatory heart disease
The threshold of [14 leukocytes/mm2 is widely accepted
for the definition of myocardial inflammation [113].
Endomyocardial biopsy allows further differentiation
between virus-positive and virus-negative inflammatory
cardiomyopathy. Human herpesvirus 6 and Parvo B19 virus
are the most prevalent viruses found in myocardial biopsy
specimens from patients with suspected myocarditis [94].
Besides direct virus mediated cardiac injury, the ensuing
immune response, mainly studied in coxsackievirus B3
small animal models of myocarditis, significantly contrib-
utes to myocardial injury and to the development of chronic
heart failure [28]. Transition into sustained myocardial
inflammation despite halted virus replication by induction
of auto-immunity further propagates local inflammation and
eventually leads to progressive myocardial fibrosis with
transition to the clinical entity DCM [27]. Animal models of
myocarditis demonstrated that the genetic background plays
an important role for modulating the adaptive immune
response, involving the cooperation of innate immune cells
and lymphocytes for induction of persistent myocardial
inflammation even after virus control as a transition to auto-
immunity [36]. However, we still do not really understand
why some patients control or even eliminate viral infection
of the heart, whereas others develop progressive deteriora-
tion leading to DCM. This also relates to the unknown
pathophysiological significance of a high prevalence of
viral genome without evidence of local inflammation, even
in healthy hearts [80, 91]. Referring to this, Kindermann
et al. [76] reported recently that the detection of immuno-
histological evidence of inflammatory infiltrates and HLA
class II expression in the myocardium rather than detection
of virus genome is of prognostic relevance in patients with
suspected myocarditis.
It is further unclear whether, in analogy to mouse models
of auto-immune myocarditis induced by vaccination against
myocardial proteins, auto-immune myocarditis develops in
patients without previous infection of the myocardium. Data
from the TIMIC trial [48] demonstrating that a differentiation
into virus-positive and -negative inflammatory cardiomyop-
athy identifies patients which could benefit from immuno-
suppression by steroids ? azathioprine indicate that auto-
immune cardiomyopathy might indeed constitute a patho-
physiologically distinct clinical entity. This does not exclude
that myocardial auto-immunity in man might always be
initiated by the adjuvant effect of concomitant myocardial or
systemic infection which might break tolerance to myocar-
dial structural components. Thus, at the moment, a careful
analysis of the presence of virus genome in the myocardium
in an experienced laboratory seems to be mandatory, at least
for further clinical trials in the field.
Heart failure with preserved ejection fraction,
myocardial hypertrophy
Chronic pressure overload also leads to the expression of
chemokines, cytokines, and infiltration of monocytes in the
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myocardium. Most evidence comes from animal models
of transverse aortic constriction. There is a well-
described pathophysiological link between inflammation
and fibrosis [13, 83], whereas the link to hypertrophy is
less well established. Especially macrophages play a
central role for development of interstitial fibrosis in
response to different stimuli. Alternatively activated
macrophages induce fibrosis by expression of proteins
like arginase, coagulation factor XIII, and TGF-b [151].
Experimentally, T-cells contribute to the pathophysiol-
ogy of myocardial fibrosis. T-cell derived IL-18 can
induce osteopontin expression and fibrosis in myocar-
dium [157]. In a mouse model of hypertension, lym-
phocyte deficient SCID mice were protected against
myocardial collagen accumulation. There was less
fibrillar collagen cross-linking and reduced activity of
the cross-linking enzyme lysyl-oxidase-like-3 compared
to wild type C57B6 mice and even higher collagen
content in Th2 biased BALB/c mice [156] indicating
that CD4? T-cells, especially modulate collagen depo-
sition in myocardium.
An expression of pro-inflammatory cytokines was also
described in myocardium from patients with aortic stenosis
[146]. Here, the pathomechanism underlying the transition
from adaptive hypertrophy to irreversible remodeling and
decompensation is incompletely understood and might also
implicate fundamental changes in the inflammatory
response.
Inflammation in heart failure with preserved ejection
fraction without overt hypertrophy has been less well
characterized. In patients with coronary artery disease and
diabetes, a small study found an association between pro-
inflammatory serum cytokines and echocardiographic evi-
dence of diastolic dysfunction [34].
In sum, clinical evidence for the implication of inflam-
mation in the development of myocardial hypertrophy and
diastolic dysfunction is sparse, although experimental
studies suggest a role especially for lymphocytes and
macrophages.
Diabetes and obesity
More and more evidence is accumulating that obesity is
associated with a systemic inflammatory response that is
characterized by endothelial cell dysfunction, oxidative
stress, and the activation of leukocytes [118]. The inflam-
matory response mediated by hormones from adipose tis-
sue, like adiponectin, might contribute to cardiac
remodeling in obesity [109]. Data on the functional status
of the myocardium in advanced obesity are ambiguous
reporting either normal or impaired diastolic, some even
impaired systolic function in different cohorts [2]. It is thus
still not quite clear, whether obesity leads to heart failure
independently from coronary heart disease.
The amount of epicardial fat was often correlated with
the severity of hypertrophy and cardiac dysfunction as
evidenced mainly by non-invasive imaging with its inher-
ent limitations in obese humans. Especially the adipocy-
tokine adiponectin, which is decreased in patients with
obesity-linked diseases, prevents left ventricular hypertro-
phy. Studies in adiponectin deficient mice revealed
increased afterload-induced hypertrophy due to impaired
activation of the activated protein kinase AMP [117].
However, the results from a variety of animal models of
diabetes and obesity are ambiguous in terms of cardiac
function and the contribution of metabolic changes con-
cerning substrate utilization and hyperglycemia on the one
hand, and adipose tissue-derived inflammation on the
other, for the myocardial phenotype observed [2, 37, 158].
Therapeutic approaches in clinical trials
Cytokine targeting
The best studied pro-inflammatory cytokine in the scenario
of heart failure is TNF-a [78, 102]. Clinical studies have
shown elevated serum levels of TNF-a in patients with
decompensated CHF, especially in those with cachexia
[107]. There is further good evidence from experimental
studies that TNF-a has an immediate negative effect on
contractile function [35, 155] and the economy of con-
traction [67]. TNF-a elicits immediate negative inotropic
effects mainly via binding to TNF-receptor 1 (TNFR1). Its
activation induces the formation of sphingosine which
reduces calcium release from the sarcoplasmic reticulum
[47, 138] and decreases b-adrenergic receptor coupling
leading to diminished sarcoplasmic reticulum calcium
pump activity [82]. Furthermore, TNF-a increases ROS
formation by uncoupling mitochondrial respiration [18]
which in turn promotes myocardial dysfunction by oxida-
tion of contractile filaments [24]. The clinical relevance of
these findings has not yet been tested by a clinical trial
testing neutralization of TNF-a in patients with acute/
decompensated heart failure.
Besides its immediate effects on the contractile perfor-
mance of the myocardium, there is also good experimental
evidence for a causal pathophysiological role of TNF-a for
the progression of myocardial remodeling leading to
chronic heart failure. Relevant mechanism demonstrated in
experimental studies are induction of cardiomyocyte
hypertrophy [154], induction of cardiomyocyte apoptosis
[160], and progressive left ventricular dilation by inducing
matrix-protease activity [89].
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Based on these extensive animal data indicating a causal
link between TNF-a and cardiac dysfunction in both the
acute and chronic setting, clinical trials were launched
which tested compounds initially developed for binding of
TNF-a in rheumatic diseases. The compound etanercept
consists of two human TNF-a receptor fragments linked to
the Fc portion of immunoglobulin G. In a phase I study,
etanercept single administration was well tolerated and
improved ejection fraction in chronic heart failure patients
[32]. Etanercept treatment over 3 months then showed
improvement in clinical parameters and ejection fraction
[15]. These pilot trials confirmed the expectations based on
animal studies and led to the initiation of large multicenter
trials (RECOVER, RENAISSANCE, RENEWAL) testing
the long-term effect of etanercept in chronic heart failure
patients with NYHA III–IV functional status and EF
B30 %. In fact, on the basis of pre-specified stopping rules,
the trials were terminated prematurely. Etanercept had no
effect on clinical status in RENAISSANCE or RECOVER
and had no effect on the death or chronic heart failure
hospitalization endpoint in RENEWAL, which analyzed
the outcome from a high dose subgroup of patients of both
trials [96].
Infliximab is a chimeric antibody binding soluble and
membrane-bound TNF-a and prevents it from binding to its
receptors. In a smaller phase II trial (ATTACH), NYHA
III–IV patients treated with lower doses of infliximab
demonstrated an increase in ejection fraction, but there was
an increased risk of hospitalization and death in a high dose
group [25].
Besides dosing and timing issues, two main points have
been worked out as possible explanations for the disillu-
sioning results [4]. First, cardiomyocytes can express TNF-
a on the cell membrane [35, 142, 143]. Binding of inflix-
imab is expected to induce apoptosis in cells expressing
membrane-bound TNF-a. Second, etanercept and inflix-
imab were suspected to prolong the half-life/bioavailability
of TNF-a. Accordingly, patients treated with infliximab
revealed increased concentrations of TNF-a [25]. This
might explain why single doses of etanercept in the phase I
study appeared to be beneficial, whereas long-term treat-
ment is obviously detrimental.
The disappointing results of the anti-TNF-a studies in
CHF patients dampened the enthusiasm in the field and
supported a common belief that the redundancy of the
immune system precludes success of specific cytokine-
targeting strategies. Thus, although other pro-inflammatory
cytokines were demonstrated to be involved in cardiac
injury and significantly correlated with clinical status and
prognosis of patients with chronic heart failure [56],
especially IL-6 has to be mentioned here [75], there was no
further prospective randomized clinical trial targeting
cytokines in chronic heart failure patients. Several drugs
approved for unrelated indications possess anti-inflamma-
tory, anti-oxidant, or immuno-modulatory properties and
were tested in patients with acute or chronic heart failure
thereafter.
Glucocorticoids
One of the first randomized trials on immuno-modulation
was conducted years before the event of the anti-TNF-a
trials. Glucosteroids were tested in a number of small
studies before the advent of current reperfusion therapy. A
number of rather small studies produced controversial
results when patients were treated in the setting of an acute
myocardial infarction to limit infarct size and improve
wound healing [88]. Later on, glucosteroids were tested in
CHF patients. In idiopathic DCM patients, prednisone
treatment induced a very modest, transient effect on ejec-
tion fraction in a subgroup with histological evidence of
inflammation [108]. Accordingly, combined treatment with
glucosteroids and azathioprine showed a beneficial on left
ventricular function in DCM patients selected by myocar-
dial HLA up-regulation in myocardial biopsy specimens
[150]. The utility of immunosuppression by steroids was
proven later in the randomized, placebo-controlled TIMIC
trial [48]. Patients with chronic biopsy proven virus-nega-
tive inflammatory cardiomyopathy benefited from predni-
sone/azathioprine treatment in terms of a significant
improvement of left ventricular ejection fraction compared
with both baseline and the control group. Yet, no long-term
follow-up data with further clinical endpoints are available
from this trial.
Thalidomide
Thalidomide was initially believed to act as an anti-TNF-a
agent. In a small pilot uncontrolled trial, thalidomide rather
increased plasma levels of TNF-a in patients with chronic
heart failure, but improved left ventricular function [54].
Thalidomide treatment for 12 weeks induced reverse
remodeling of the left ventricle in a subsequent small
randomized trial. Improvement in LVEF was accompanied
by a decrease in matrix metalloproteinase-2 suggesting a
matrix-stabilizing rather than an anti-inflammatory effect
[55].
Statins
Statins are well known for their ‘‘pleiotropic’’ effects
besides cholesterol lowering. Immuno-modulatory and
anti-inflammatory effects have been described which in
part, inter alia, relate to attenuation of T-cell activation by
repression of MHC-II expression [85]. Rosuvastatin was,
therefore, studied in two clinical trials in patients with
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chronic heart failure. The CORONA trial tested the effi-
cacy of rosuvastatin in a mixed CHF population [77].
Rosuvastatin did not reduce the primary outcome, although
the drug did reduce the number of cardiovascular hospi-
talizations. In the unrelated GISSI-HF trial, rosuvastatin
was also tested in patients with chronic heart failure, irre-
spective of underlying cause and left ventricular ejection
fraction. Here, the drug did not affect pre-specified clinical
outcomes [134]. Therefore, based on a fairly large cohort
of chronic heart failure patients studied in clinical trials,
rosuvastatin treatment could not prove a benefit as adjunct
to current heart failure medication.
Pentoxifylline
Pentoxifylline is a phosphodiesterase inhibitor which is
approved for the treatment of peripheral vascular disease.
The initial rationale for using pentoxifylline was due to its
ability to inhibit TNF-a transcription. Yet, not all studies
could link improvements in clinical outcome to a concor-
dant effect on TNF-a modulation [116].
In several clinical trials, pentoxifylline therapy was
reported to reduce circulating levels of C-reactive protein,
FASL, and TNF-a in heart failure patients. In those small
heart failure trials, pentoxifylline also improved ejection
fraction and functional outcome [119, 120, 122, 124].
However, a clinical trial from an unrelated group demon-
strated that treatment with pentoxifylline had no significant
effect on left ventricular function, inflammatory cytokines,
and symptoms in patients with cardiomyopathy of various
etiologies [9]. Pentoxifylline was also tested in women
with peripartum cardiomyopathy and produced promising
effects on a combined outcome endpoint [121]. Whereas
most studies included patients with mild-to-moderate heart
failure, another trial tested pentoxyphilline in a small
NYHA IV patient cohort. This prospective, placebo-con-
trolled study revealed an increase in ejection fraction after
1 month [123].
Anti-oxidants
Oxidative stress is believed to play a causative role in the
evolution of the heart failure syndrome mainly on the basis
of experimental studies. On the cellular level, reactive
oxygen species can activate multiple signaling pathways,
including MAP kinases and nuclear factor-jB [69]. This
induces expression of pro-inflammatory cytokines like
TNF-a, which again promotes ROS formation and pro-
apoptotic signaling as a potential positive feedback
mechanism after myocardial infarction or chronic pressure
overload [153]. Myofibrillar protein oxidation was shown
in an animal model of coronary microembolisation [24]
and a pacing-induced heart failure model [60]. Of note,
oxidative modification of myofibrillar proteins was subse-
quently also found in human failing hearts [23, 59]. A
potential role for generation of oxidative stress was further
underscored by the clinical observation that there is a
significant positive correlation between the clinical class of
heart failure and several biochemical parameters of oxi-
dative stress in patients with chronic heart failure [73].
Therefore, a randomized trial was conducted to study
whether oxypurinol, a xanthine oxidase inhibitor expected
to reduce the production of reactive oxidant species, pro-
duces clinical benefits in patients with NYHA class III/IV
heart failure. Oxypurinol did not produce clinical
improvements [57]. The effect of allopurinol on diastolic
function in chronic heart failure patients was further stud-
ied in a recent, yet unpublished, trial (NCT00477789).
Another small double-blinded controlled randomized
trial aimed to determine whether vitamin E supplementa-
tion of patients with advanced heart failure (NYHA III/IV)
would modify levels of oxidative stress and improve
functional status and prognosis. However, supplementation
with vitamin E did not result in any significant improve-
ments [74].
Despite the theoretical potential of adding anti-oxidants
to standard heart failure medication, which might have
been underestimated on the basis of these rather small
trials, it has to be mentioned that standard heart failure
medication already includes drugs with anti-oxidant prop-
erties, especially ACE inhibitors and angiotensin receptor
blockers [140].
On the other hand, the addition of a fixed dose of iso-
sorbide dinitrate plus hydralazine to standard therapy for
heart failure improved survival among black patients with
advanced heart failure in the AHeFT trial [135, 136]. This
drug combination includes a nitric oxide donor (isosorbide
dinitrate) and an antioxidant (hydralazine) to protect NO
from degradation. Anti-oxidant mechanisms improving NO
bioavailability and, thus, endothelial dysfunction were
discussed to contribute to the observed effect [40]. The
results of AHeFT indicate that there might be considerable
variation in the significance of the role of oxidative stress
and endothelial function according to ethnical background.
Immune modulation by modified autologous blood
Autologous blood exposed ex vivo to heat and oxidative
stress induces anti-inflammatory effects in animal models
[106]. The precise mechanism has not been studied, espe-
cially in humans. One might speculate that apoptotic cells
contained in the autologous blood could have an important
contribution to the immuno-modulatory effect [147]. Based
on these experimental results, a small randomized phase II
study was conducted in NYHA III–IV heart failure
patients. This study demonstrated a significantly reduced
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risk of death and hospitalization [144]. The subsequent
placebo-controlled ACCLAIM trial did not find a signifi-
cant reduction of hospitalization or mortality in over 2,400
NYHA III–IV patients studied during 12 months [141].
PUFA
Considerable epidemiological data found an association of
omega-3 polyunsaturated fatty acid (x-3 PUFA) intake,
mainly from fish oils, and cardiovascular endpoints
(reviewed in [87]). Reduction of coronary events seems to
contribute most to the total effect. A recent prospective
study of nearly 60,000 Japanese people with a high intake
of fish, followed-up for over 12 years, revealed an inverse
association between fish, PUFA consumption, and mor-
tality, especially for heart failure [152]. PUFAs have
multiple immuno-modulating properties including effects
on arachidonic acid metabolism and peroxisome prolifer-
ator-activated receptors (PPARs) [103].
Dietary PUFA supplementation was studied by the
Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico-Heart Failure (GISSI-HF) study, a
large-scale clinical trial in a chronic heart failure cohort.
This trial showed a moderate, albeit significant benefit of
x-3 PUFA in addition to standard heart failure medication
[133]. The mechanism behind it is not yet clear. The
beneficial effect on mortality seemed not to rely on pre-
vention of sudden cardiac death as in the GISSI prevention
trial [1]. Recently, in a small double-blind, randomized,
controlled trial two doses of PUFA were tested in patients
with advanced, non-ischemic heart failure. Treatment with
PUFA for 3 months led to a dose-dependent increase of
LVEF [104].
Based on these trials the clinical relevance of PUFAs in
chronic heart failure patients is still not clear. Thus, PUFA
supplementation received a class IIb, level of evidence B
recommendation in the most current European heart failure
guideline [99].
Immuno-adsorption, antibody neutralization
There is a considerable proportion of patients with chronic
heart failure, especially DCM, which have auto-antibodies
[21]. The high prevalence of viral genome in idiopathic
forms [92] and the presence of myocardial auto-antibodies
in asymptomatic relatives to familial DCM patients [20,
22] puts the heterogeneous clinical entity of DCM in an
exceptional immunological position. The pathophysiolog-
ical relevance of auto-antibodies in humans with heart
failure has not yet been finally defined, whereas there is
experimental evidence from rodent models that auto-anti-
bodies especially against the b1-adrenergic receptor can
induce a dilated cardiomyopathy phenotype [72]. The
functional effect of b1-adrenergic receptors, which are of
note also observed in up to 10 % of healthy control indi-
viduals, on intracellular b-adrenergic signaling in cardio-
myocytes varies depending on their effect on receptor
conformation and its internalization [12]. The binding sites
for the pathogenic b1-adrenergic receptor antibodies are
confined to portions of the extracellular loop domains
where they induce agonist-like effects finally leading to
apoptosis [29]. The presence of stimulating b1-adrenergic
auto-antibodies was reported to independently predict the
increased all-cause and cardiovascular mortality risk in a
prospective study following patients with DCM over
10 years [129]. The prevalence of stimulating b1-adren-
ergic auto-antibodies was 26 % of patients with DCM in
this cohort.
Several related studies have demonstrated that immuno-
adsorption induces improvement of left ventricular func-
tion in patients with DCM [39, 125, 126]. It was also found
that patients with auto-antibodies that induce cardio-
depressant effects in vitro benefit most from this treatment
[3, 128]. Immuno-adsorption with subsequent immuno-
globulin substitution led to a reduction in the number of
leukocytes and HLA class II expression in the myocardium
of DCM patients, indicating that inflammatory activity
within the myocardium is in fact reduced by treatment,
whereas the extent of fibrosis was unchanged [127]. These
promising results stimulated the design of a larger ran-
domized trial on immune-adsorption which is currently
underway (NCT00558584). As a different approach, there
is another ongoing clinical trial evaluating a blocking
peptide against stimulating b1-adrenergic auto-antibodies
in DCM patients (COR-1 NCT01391507) [105].
Immunoglobulins
A wide array of potential immuno-modulating effects has
been attributed to intravenous immunoglobulins which
demonstrated therapeutic efficacy in a variety of diseases
with unrelated pathophysiology. However, clinical study
results for treating heart failure are ambiguous. A small
randomized trial in patients with symptomatic heart failure
demonstrated a change in the balance between inflamma-
tory and anti-inflammatory cytokines by immunoglobulin
treatment. This effect was significantly correlated with an
improvement in LVEF [52]. Another small randomized
trial proved no effect of immunoglobulin treatment [101].
The underlying biological mechanism for the potential
beneficial effects of immunoglobulins in DCM remains to
be determined. A comprehensive overview of potential
mechanism was recently provided by Gelfand [49]. Neu-
tralization of auto-antibodies is one mechanism often dis-
cussed to contribute to the beneficial effect of
immunoglobulins in auto-immune disease. However, a
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study in patients with DCM and ischemic cardiomyopathy
found that intravenous immunoglobulins did not neutralize
b1-adrenergic auto-antibodies [86]. Interpretation of the
heterogenous study results is especially hampered by the
fact that in most studies no comprehensive histological
information from endomyocardial biopsies of all partici-
pants was available. Of note, there is a high rate of viral
persistence in the myocardium of patients with idiopathic
DCM [92]. Elimination of virus persistence was further
demonstrated to improve the prognosis in a relatively small
cohort of DCM patients [81]. Immunoglobulins have
especially been shown to possess both anti-inflammatory
and antiviral effects in experimental myocarditis [130].
This led to clinical evaluation of intravenous immuno-
globulins for the treatment of viral cardiomyopathy. The
most comprehensive current European Study on the Epi-
demiology and Treatment of Cardiac Inflammatory Disease
(ESETCID) trial includes an elaborate treatment protocol
treating cytomegalovirus, adeno-, and Parvo B19 positive
inflammatory DCM patients with immunoglobulins [70,
95]. The final publication of the results of the trial is still
pending.
Given the efficacy of immunoglobulins in attenuating
virus replication in myocardium, it might thus be the case
that the high prevalence of latent virus infection in the
myocardium of DCM patients contributes to the positive
effects of immunoglobulins in heterogeneous populations
of DCM patients included in the above-mentioned trials.
Bone marrow derived cells/progenitor cells
The field of therapeutic stem cell therapy has made great
advance in the last years due to a number of clinical studies
which are underway or just have been completed [58].
Most animal studies could not attribute the observed
functional effects to regeneration via local engraftment and
proliferation. Instead, paracrine effects of the transferred
cells are generally believed to play a central role. Immuno-
modulation by these cells might contribute to the overall
beneficial effects of a variety of cell types. Especially for
mesenchymal stem cells, manifold immuno-modulating
properties have been described in this context [145]. Others
have speculated that apoptotic cells, within the transferred
cell preparations inducing immunosuppression, might play
an important role [64, 90, 139]. This hypothesis would help
explaining, why such a great variety of unrelated cell types
produced an effect in experimental studies.
Most clinical trials were designed to improve repair/
regeneration of the injured heart in the setting of myocar-
dial infarction, while few studies yet addressed chronic
heart failure patients.
The TOPCARE-CHD trial tested intracoronary treat-
ment with either bone marrow cells or peripheral
progenitor cells in a crossover design in patients with
chronic ischemic heart failure. Transplantation of bone
marrow cells was associated with moderate but significant
improvement in the left ventricular ejection fraction after
3 months [7] and even improved survival in a registry-
based analysis [6].
Another group reported similar promising results of
intramyocardial delivery of bone marrow cells in chronic
myocardial infarction and advanced chronic heart failure
patients [111].
It was speculated that progenitor cell therapy might be
more promising in non-ischemic heart failure patients, as
the functional capacity of endogenous progenitor cells is
more severely impaired in patients with ischemic cardio-
myopathy than in DCM patients [137]. In the transplanta-
tion of progenitor cells and functional regeneration
enhancement pilot trial in patients with non-ischemic
dilated cardiomyopathy (TOPCARE-DCM) trial, autolo-
gous intracoronary bone marrow application resulted in
significant improvement in LVEF at 1 year [41]. However,
as it was often the case in progenitor cell trials, no adequate
control group was studied in parallel in this pilot trial.
Recently, 5-year follow-up data of a well-designed,
albeit not placebo-controlled and not double-blinded, ran-
domized study investigating the long-term effects of in-
tracoronary administration of G-CSF-mobilized CD34?
stem cells in patients with DCM were reported. During the
follow-up period, cell therapy was associated with a
moderate but significant improvement in cardiac function
(mean increase of EF 5.7 %), coming along with an
improved exercise capacity and even decreased mortality
[148]. Interestingly, homing efficiency correlated with
changes in EF indicating that transplanted cells elicited
local effects in myocardium rather than inducing a sys-
temic, e.g., immuno-modulating, effect.
However, none of the trials in chronic heart failure
patients deeply assessed parameters of immune activation.
Therefore, the contribution of putative immuno-modula-
tory effects of transferred cell preparations cannot be
determined yet.
New translational targets
There is a great variety of potential therapeutic targets in the
field of pro-inflammatory signaling in heart failure. Perhaps,
most experimental evidence has accumulated in experimental
models of post-myocardial infarction heart failure concerning
toll-like receptor and intracellular NFjB signaling (for
review [42–44, 68]). However, the universal role of this
system in innate immunity might induce unforeseeable side
effects, especially concerning susceptibility to infection and
auto-immunity. Thus, despite a good understanding of this
Page 8 of 19 Basic Res Cardiol (2013) 108:356
123
signaling system, no therapeutic trial addressing chronic
heart failure has been launched so far in this field.
Besides numerous signaling molecules like cytokines,
chemokines, and their related receptors which have
meanwhile been identified and targeted in animal studies
two novel targets should be highlighted here.
Complement
Complement is activated during acute and chronic cardiac
injury in different animal models. Michael Carroll’s group
demonstrated complement activation by ischemia/reperfu-
sion in different organs by a single IgM clone that recog-
nizes a neo-epitope on hypoxic cells [65, 159]. This clone
is produced by a subset of B-lymphocytes called B-1 cells,
the major source for natural IgM antibodies. Carroll’s
group subsequently identified the relevant antigen as non-
muscle myosin heavy chain II which becomes accessible to
natural IgM after cell injury [159]. No experimental data
are published on the role of natural IgM in chronic heart
failure yet.
Glycoprotein-130 (gp130) is the common receptor of
IL-6, which is elevated in patients with chronic heart
failure [5]. Cardiomyocyte-specific gp130 mutant mice
have a normal myocardial phenotype at baseline, but
increased mortality and development of heart failure after
experimental myocardial infarction. This was associated
with increased expression of complement-activating man-
nose-binding lectin (MBL) [62]. This animal model sug-
gested a link between IL-6 and chronic myocardial injury
induced by complement activation.
MBL and IgMs are independent trigger mechanisms for
initiating the complement cascade. Both pathways con-
verge on the activation of complement component C3 into
cleaved C3a. Mice deficient for either C3 or the membrane
receptor for C3a (C3aR) is protected against chronic left
ventricular remodeling after myocardial infarction (own
unpublished results).
Accordingly, a prospective study in a chronic heart
failure cohort comprising 182 patients demonstrated that
complement activation is strongly linked to the outcome in
chronic heart failure. Especially, high levels of activated
C3, C3a, predicted cardiovascular events such as hospi-
talization and mortality [50]. However, studies in CHF
patients are lacking yet. There are just clinical data for
complement inhibition in the setting of acute ischemia.
Whereas C1 esterase inhibitor treatment showed promising
effects in surgically revascularized STEMI patients [38],
anti-C5a therapy had no effect in STEMI patients [51].
Therefore, there is a considerable experimental evidence
that at least after ischemic myocardial injury, there is an
ongoing complement activity in myocardium. Interventions
inhibiting complement activation, especially the central
component C3/C3a may represent a novel target for pre-
vention and treatment of chronic heart failure after large
myocardial infarction.
Regulatory T-cells
Most immuno-mechanisms studied in chronic heart failure
till date address innate immunity, whereas adaptive
immune mechanisms have gained much less interest so far.
Recently, CD4? regulatory T-cells came especially into
focus.
Regulatory CD4? T-cells comprise a subset of thymus-
derived T-cells which are characterized by intracellular
expression of the transcription factor Foxp3 [115]. By
means of cell surface staining for FACS analysis they are
often defined as CD4?CD25?CD127lowCD3? T-cells.
Regulatory T-cells are well known for preventing autore-
active immune responses which are associated with chronic
myocardial diseases, such as auto-antibody formation [19].
As discussed below, there is further evidence from animal
studies that they modulate fibrosis, cardiomyocyte hyper-
trophy, and monocyte activation in the myocardium, pro-
cesses which constitute central mechanisms in myocardial
remodeling (Fig. 2).
Regulatory CD4? T-cells might mediate part of the
clinical effect of immuno-modulating therapeutic princi-
ples, which was already tested in clinical studies: intrave-
nous immunoglobulins beneficially modulate several
unrelated auto-immune diseases. As discussed above,
clinical trials indicate that they might also have beneficial
Fig. 2 CD4? regulatory T-cells modulate the function of T-effector
cells and B-cells which leads to e.g., autoantibody production which
has been found to contribute to cardiac dysfunction in several heart
disease. Besides their classical regulatory role on adaptive immune
response they have also been demonstrated to influence monocyte
differentiation, which again influences fibrosis, and to attenuate
myocardial hypertrophy
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effect in inflammatory cardiomyopathies. It was speculated
that sustained peripheral expansion of antigen-specific
CD4?CD25?Foxp3? regulatory T-cells might contribute
to their therapeutic effect [93].
Besides possible effects by neutralizing autoreactive
antibodies, a recent study indicated that immuno-
adsorption also modifies T cell-mediated immune reac-
tions. Immuno-adsorption in patients with DCM was
associated with a significant increase of regulatory T cells
(CD4?CD25?CD127low), and a decrease of activated T
cells (CD4?CD69? and CD8?CD69? cells and CD28? T
cells) [17]. The frequency of circulating regulatory
T-cells also correlated with the hemodynamic response to
immuno-adsorption [16].
Furthermore, reduced numbers and impaired suppres-
sive function of CD4?CD25? Foxp3?CD127low cells were
found in peripheral blood of patients with chronic heart
failure [131]. There are also some experimental data indi-
cating, that loss of functional regulatory T-cells is not just
an epiphenomenon in chronic heart failure, but might also
be relevant for myocardial remodeling in different disease
states. We have recently demonstrated that myocardial
infarction rapidly induces activation of proliferation of
CD4?CD25?Foxp3? T-cells in heart draining lymph nodes
[66]. Our data indicate that the recognition of an antigen
released from the injured myocardium is responsible for
this activation process. Transfer of CD4?CD25? T-cells
was further reported to attenuate myocardial remodeling
after experimental myocardial infarction in mice [97, 132].
Another group reported that transfer of CD4?CD25? cells
ameliorates cardiac hypertrophy and fibrosis in response to
angiotensin II [84]. Of note, this was also associated with
an amelioration of arrhythmogenic electric remodeling.
Therefore, therapeutic expansion and activation of reg-
ulatory T-cells might tackle several immunological mech-
anisms contributing to the heart failure syndrome:
mitigation of the expression of pro-inflammatory cyto-
kines, suppression of auto-antibody production, and mod-
ification of recruitment, and differentiation of monocytic
heart infiltrating cells contributing to both tissue repair and
remodeling (own unpublished data).
Besides transfer of autologous, ex vivo enriched regula-
tory T-cells, therapeutic expansion/activation in vivo might
be more promising [31, 114]. Mucosal application of anti-
gens is able to potently induce regulatory T-cells with
specificity against it. Thus, mucosal administration of pro-
teins induces secretion of anti-inflammatory cytokines, such
as IL-10 at the anatomical site where the protein localizes.
Frenkel et al. [46] have demonstrated that nasal application
of troponin reduces infarct size after myocardial ischemia-
reperfusion. This principle has not yet been tested in chronic
heart failure, but might be a rather specific means of tuning
immunity within the diseased myocardium.
Histone deacetylases (HDACs) catalyze the removal of
acetyl groups from a variety of proteins. HDACs have been
studied mainly in the context of chromatin, where they
contribute to epigenetic regulation of gene expression by
deacetylating nucleosomal histones. HDAC inhibitors
stimulate Treg production by promoting acetylation of the
Foxp3 transcription factor, which is a key regulator of Treg
differentiation [149]. On the other hand, HDAC inhibitors
beneficially affect myocardial remodeling, especially
pathological hypertrophy in animal models [98]. The
mechanism by which they do that is not quite clear, but
induction of regulatory T-cells might significantly con-
tribute to their effect. Therefore, this kind of drug might
constitute a very interesting new therapeutic principle for
targeting both inflammation and pathological fibrosis and
hypertrophy in the context of chronic heart failure.
Conclusion
Most completed trials on immuno-modulatory treatments
were rather small including less than 100 patients/group.
Data from randomized, placebo-controlled studies includ-
ing more than 1,000 patients exist for TNF-a antagonists
[25, 96]. The rosuvastatin trials, GISSI [134] and COR-
ONA [77], as well as the ACCLAIM trial studying
immuno-modulation by ex vivo modified autologous blood
[147], also included more than 1,000 patients. All these
chronic heart failure trials failed to demonstrate a benefit
by meeting pre-specified endpoints. The sole large-scale
randomized trial that was able to reveal some benefit was
GISSI-HF which found a moderate, albeit significant ben-
efit of x-3 PUFA in addition to standard heart failure
medication including a reduction in total mortality [133].
Why did so many clinical trials, which were all laun-
ched on the basis of promising experimental data, show
no additional benefit to current standard heart failure
therapy?
As one hypothetical explanation, it must be mentioned
here that standard drugs addressing neuro-humoral activa-
tion, which are obligatory co-medication in current heart
failure trials also might have relevant effects on inflam-
matory activation. Especially ACE inhibitors have
immuno-modulatory properties, as components of the
renin–angiotensin–aldosterone system are expressed on
leukocytes. Especially, the angiotensin–aldosterone system
in T-cells came recently into the focus. T-cells contain an
endogenous renin–angiotensin system that modulates pro-
inflammatory T-cell function [63]. Blocking angiotensin-
converting enzymes on the other hand induces regulatory
CD4?Foxp3? T-cells which have the ability to dampen
pathological inflammation and auto-immune by a variety of
mechanisms [110]. Accordingly, it was reported that
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enalapril decreases IL-6 levels in patients with chronic
systolic heart failure [53]. It remains unclear, however,
whether this effect is due to a direct immuno-modulatory
effect of the ACE inhibitor or rather a consequence of the
improved overall hemodynamic and functional status under
this medication. This relates to a central, yet unresolved
question in the field, whether inflammation in heart failure
is causative for or merely a consequence of heart failure.
One might ask whether there is still a justifiable ratio-
nale for conduction of future clinical trials targeting
inflammation as adjunct to our current pharmacological
heart failure therapy. In our opinion, there is good exper-
imental evidence that inflammation causally contributes to
myocardial dysfunction and, thus, still constitutes a rea-
sonable and promising therapeutic target, but some ques-
tions have to be carefully addressed before designing a
clinical trial.
First, which patients are best candidates for immuno-
modulating treatment modalities? The hope to find a
therapeutic principle that fits in all clinical scenarios of
heart failure seems to be more and more unrealistic. It
might be more promising in the future to individually
characterize the immunologic status of a patient to decide
whether he might benefit from the targeted immuno-mod-
ulation at the present time. Especially in patients with
idiopathic DCM, this will have to include endomyocardial
biopsies to gain more insights to define the present status of
intramyocardial inflammatory activity and, especially, to
exclude ongoing viral activity. Infectious (especially virus
induced) cardiomyopathy might become accessible to a
completely different treatment in the future. Immuno-
adsorption in patients with auto-antibodies, which have
been evaluated for their cardio-specificity and toxicity,
exemplifies such a first individualized approach [128].
Complementary to the still underused endomyocardial
biopsy-based analyses, which have inherent limitations
mainly due to sampling errors, there is an urgent need for
identifying novel biomarkers or imaging modalities to
identify CHF patients who could benefit from immuno-
modulation.
Monitoring of systemic, i.e., serum parameters of
inflammation, especially cytokines, does likely not reflect
myocardial inflammation, but is rather a marker of the
overall clinical status. Therefore, one cannot conclude from
the currently available serum parameters, which are often
the only available biomaterial to monitor immunity in
clinical studies, on the local effect on myocardial inflam-
mation. Thus, at the moment, the real biological effect of
immuno-modulating therapies, putatively beneficially
influencing myocardial inflammation, cannot readily
become assessed in clinical studies.
As a different approach, as opposed to CHF patients,
the wound healing phase after an acute myocardial
infarction, which is the most important cause for heart
failure in the Western word, might constitute another
attractive phase for preventive immuno-modulation [42].
Experimental animal studies indicate that there might be
an early window for intervention to tune the immuno-
logical response to cardiac injury limiting infarct
expansion and induction of ongoing remodeling in the
remote myocardium.
Second, how can we better identify immuno-modulating
treatment principles tested in animal models to be suited
for further translational clinical evaluation? Here, pre-
clinical testing of therapeutic modalities warrants more
attention. Several treatment modalities went into clinical
trials, mainly on the basis of promising effects in rodent
models, indicating that immuno-modulation, as evidenced
e.g., by cytokine expression profiling or genetic lack/gain
of function studies, might be causative. Here, we have to
pay more attention on the transferability of immunological
phenomena from small animal models to man. This does
not only relate to the estimation of the putative therapeutic
impact, but also to potential side effects. In addition, before
going into man for phase I/II trials, large-animal studies
have to be advocated. However, even a very good under-
standing of the biological mechanism of an immuno-
modulating therapeutic tested in different species does not
prevent from unexpected effects in man which can, at best
lead to lack of efficacy, but also to deleterious side effects
[71].
Also essential, but widely underestimated, factors like
age [11], co-medication, comorbidity, and last but not least,
gender have to be drawn into consideration as much as
possible in animal studies before thinking about clinical
trials.
Therefore, we pledge for even greater effort spent on
translational cardio-immunological research which goes
beyond phenomenological description of beneficial effects
on myocardial function and remodeling and its association
with parameters of inflammation. Given the inherent lim-
itation to monitor the systemic and, especially local
immunological processes within the myocardium in
patients, a deep understanding of the biological effects of a
therapeutic principle in different experimental models is
vital before starting clinical studies.
In addition, in this context, as many therapeutically
principles have only been tested in the chronic myocardial
infarction heart failure mouse model, other models of
chronic heart failure, especially models of genetic and
inflammatory cardiomyopathies, should receive more
interest in the future.
Summing up the current evidence from both experi-
mental and clinical studies discussed here, we would like to
conclude that inflammation is a promising therapeutic
target in the setting of CHF. Current state of evidence from
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clinical trials indicates that unspecific immuno-modulation,
e.g., by steroids or immuno-adsorption, holds some
promise especially in the ‘‘orphan’’ field of idiopathic/
inflammatory, non-viral DCM (see Table 1). Thus, we can
await even greater benefit from more targeted or even
individualized treatment modalities which are eagerly
awaited in the field as complementary therapeutic means to
our current heart failure drugs.
Table 1 Randomized clinical studies evaluating immuno-modulating/anti-inflammatory treatments in CHF patients as discussed in the
manuscript








Etanercept [32] 18 23/29 % III Mixed Improved functional parameters and EF
[15] 47 16–21 % III–IV Mixed
[96] 2,048 22–24 % III–IV Mixed Improved EF and remodeling parameters
Infliximab [25] 150 23–25 % III–IV Mixed Combined analysis of RECOVER and
RENAISSANCE trials: no effect on clinical
composite endpoint
No clinical improvement, combined risk of death
from any cause or hospitalization for heart
failure increased in subgroup
Prednisone [108] 102 18 % nd DCM Transient improvement in EF
Prednisone ? azathioprine [150] 202 24 % II–IV DCM Improved secondary endpoint of LV volume and
EF
[48] 85 27 % II–IV Virus-negative
myocarditis
Improved EF and NYHA class
Thalidomide [55] 56 25 % II–III Mixed Improved EF
Rosuvastatin [77] 5,011 31/33 % II–IV Mixed No effect of primary combined endpoint
[134] 4,631 33 % II–IV Mixed No effect of primary combined endpoint
Pentoxifylline [119] 39 24/25 % II–III DCM Improved functional status after 6 months
[120] 49 23 % II–III DCM Improved functional class, and EF
[122] 28 25/22 % II–III DCM Improved EF and functional status
[123] 18 13/16 % IV DCM Improved EF
[124] 38 23/27 % II–III ICM Functional improvement
Isosorbide
dinitrate ? hydralazine
[135] 1,050 24 % III–IV Mixed Improved composite endpoint in African–
Americans. Study terminated prematurely for
early benefit
Vitamin E [74] 56 23 % III–IV Mixed No clinical improvement, no effect on markers
of oxidative stress after 12 weeks on treatment
Autologous modified
blood
[144] 75 22 % III–IV Mixed Reduced mortality and risk of hospitalization
after 6 months
Polyunsaturated fatty acids [133] 7,046 33 % II–IV Mixed Improved composite endpoint
[104] 43 24 % III–IV Non-ICM Dose-dependent improved EF
Immuno-adsorption [126] 22 28/27 % III–IV DCM Improved EF, without control group
Immunoglobulins [52] 40 26/28 % II–III Mixed Improved EF
[101] 62 25 % I–IV DCM,
myocarditis





I–III ICM Improved EF 3 months after infusion of bone
marrow derived cells
[111] 109 27 % II–IV ICM Improved functional status and EF 12 months
after infusion of bone marrow derived cells
[148] 110 24/26 % III DCM Improved functional status and EF after 5 years
of infusion of CD34? cells
If mean EF was not equal, EF for placebo/treatment groups were indicated
nd not determined, ICM ischemic cardiomyopathy, DCM dilative cardiomyopathy
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